STOCK TITAN

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) will host a virtual investor day to showcase neffy® (epinephrine nasal spray) on March 7, 2024. The event features presentations by ARS management and renowned allergists, with a live Q&A session. The webcast can be accessed on the company's website, with a replay available for 90 days.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that it will host a virtual investor day highlighting neffy® (epinephrine nasal spray) on Thursday, March 7, 2024, at 1:00 p.m. ET. To participate in the event, please register here.

The event will include presentations by members of the ARS management team and by two distinguished allergists:

  • Jonathan Spergel, M.D., Ph.D., Professor of Pediatrics and Chief of the Allergy Program at Children’s Hospital of Philadelphia
  • Thomas B. Casale, M.D., Professor of Medicine and Pediatrics and Chief of the Allergy/Immunology Division at University of South Florida

A live question and answer session will follow the formal presentations.

The neffy Investor Day webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

ARS Media Contact:
Laura O’Neill
Laura.oneill@finnpartners.com

ARS Pharma Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com


FAQ

When will ARS Pharmaceuticals host the virtual investor day for neffy®?

ARS Pharmaceuticals will host the virtual investor day for neffy® on March 7, 2024.

What is neffy®?

neffy® is an epinephrine nasal spray developed by ARS Pharmaceuticals, Inc.

Who will be presenting at the neffy® Investor Day?

The event will feature presentations by members of the ARS management team and distinguished allergists, Jonathan Spergel, M.D., Ph.D., and Thomas B. Casale, M.D.

Where can the webcast of the neffy® Investor Day be accessed?

The webcast can be accessed through the Events & Presentations page in the Investors & Media section of ARS Pharmaceuticals' website.

How long will the replay of the webcast be available?

A replay of the webcast will be archived on the Company’s website for 90 days.

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

SPRY Rankings

SPRY Latest News

SPRY Stock Data

1.52B
96.94M
23.21%
65.9%
12.29%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO